ArticleResearch square2025
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.
Theodoros Karantanos, Nour Naji, Taha Ahmedna, J Peske, Xinghan Zeng, Brandy Perkins, Zanshé Thompson, Tushar Nichakawade, Bum Lee, Evangeline Watson and 14 more
Abstract readPreprint
In one paragraphArticle in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
24 authors.
Theodoros Karantanos
Nour NajiJohns Hopkins University.
Taha AhmednaJohns Hopkins University.
Xinghan Zengjohns hopkins university.
Brandy PerkinsJohns Hopkins University.
Zanshé ThompsonDepartment of Medicine, Division of Hematology, The Johns Hopkins University School of Medicine.
Tushar NichakawadeJohns Hopkins University.
Bum LeeJohns Hopkins University.
Evangeline WatsonJohns Hopkins University.
Theodora ChatzilygeroudiJohns Hopkins University.
Li LuoJohns Hopkins University School of Medicine.
Bogdan PaunJohns Hopkins University.
Melanie KlausnerJohns Hopkins University School of Medicine.
Yuju AnJohns Hopkins University.
Teodora SupeanuJohns Hopkins University.
Ivana GojoJohns Hokins University.
Gabriel GhiaurThe Johns Hopkins University School of Medicine.
Mark LevisJohn Hopkins.
Richard John JonesSidney Kimmel Comprehensive Cancer Center.
Styliani KaranikaJohns Hopkins University.
Funding
T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer ResearchT32CA153952 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz · 2015 to 2026
$3.5MTCR Targeting Antibodies for the Treatment of T cell CancersK08CA270403 · NCI · JOHNS HOPKINS UNIVERSITY · PI Suman Paul · 2022 to 2026
$1.1MCCRL2 as a Regulator of Growth and Novel Target in Myelodysplastic SyndromeK08HL168777 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Theodoros Karantanos · 2023 to 2026
$687kNCI NIH HHS K08 CA270403NCI NIH HHS T32 CA153952NHLBI NIH HHS K08 HL168777
6 · The paper itselfAbstract
Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) with high-risk features including
Identifiers
PMID41282192
PMCPMC12636720
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390